SCHEMBL236785

SCHEMBL236785

C#CC(O)(CCC)CCC

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9690973 0.90 FDPS (0.31) FDPS
SCHEMBL2022763 0.89
SCHEMBL233642 0.83 FDPS (0.33) FDPS
SCHEMBL1811498 0.81 FDPS (0.41) FDPS
SCHEMBL5806390 0.79 FDPS (0.43) FDPS
SCHEMBL28634054 0.77
SCHEMBL235810 0.75
SCHEMBL737364 0.75 FDPS (0.38) FDPS
SCHEMBL236550 0.74
SCHEMBL28944613 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120058807-A Platinum complex and preparation method and application thereof 广东盛唐新材料技术有限公司 2025-05-30 CN claimed
CN-120058807-A Platinum complex and preparation method and application thereof 广东盛唐新材料技术有限公司 2025-05-30 CN disclosed
US-9464033-B2 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-10-11 US disclosed
US-9464033-B2 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-10-11 US disclosed
US-9464033-B2 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-10-11 US disclosed
US-9452153-B2 Amine derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-09-27 US disclosed
US-9452153-B2 Amine derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-09-27 US disclosed
US-9452153-B2 Amine derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-09-27 US disclosed
US-20160193181-A1 AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2016-07-07 US disclosed
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2016-05-26 US disclosed
US-5128480-A Reacting butenediols, ethynylalkylcarbinols or their acylates in sulfuric acid with a hydrazine compound using iodine or an iodine compound catalyst BASF AKTIENGESELLSCHAFT (DE) 1992-07-07 US disclosed
EP-0456972-A1 Surface modification of a polyimide International Business Machines Corporation (US) 1991-11-21 EP disclosed
US-4749449-A PLATING ON CATALYZED THROUGH HOLE WALL IN PATTERENED CONDUCTIVE AND INSULATING LAYERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-06-07 US disclosed
US-4371676-A FREE-RADICAL CATALYSTS BASF AKTIENGESELLSCHAFT (DE) 1983-02-01 US disclosed
US-4201725-A TRISUBSTITUTED METHYL-N-METHYLAMINE, PARKINSON*S DISEASE, ANTISPASMODIC AGENTS LABAZ (FR) 1980-05-06 US disclosed
US-4091107-A RENAL VASODILATORS, ANTICLOTTING AGENTS, GROWTH HORMONE RELEASE, REGULATORS OF IMMUNE RESPONSE MERCK & CO., INC. (US) 1978-05-23 US disclosed
US-4057644-A PARKINSON'S DISEASE LABAZ (FR) 1977-11-08 US disclosed
US-4048334-A PARKINSON*S DISEASE, NEUROLEPTIC AGENTS LABAZ (FR) 1977-09-13 US disclosed
US-4033996-A RENAL VASODILATORS, ANTITHROMBOSIS, GROWTH HORMONE RELEASING MERCK & CO., INC. (US) 1977-07-05 US disclosed
US-4026925-A PARKINSON*S DISEASE LABAZ (FR) 1977-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160193181-A1 AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, AADAT FDPS 2096/4885
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 FDPS 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.